- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07721506
A Clinical Trial to Evaluate the Effects of the Edge+Ease PM+AM System on Mood, Mental Clarity, Sleep Quality, and Digestive Wellbeing
This is a decentralized, single-arm, open-label clinical trial evaluating the effects of the Edge+Ease PM+AM dietary supplement system on sleep quality, mood, mental clarity, focus, and digestive comfort in 35 generally healthy adults aged 18-65 years over 12 weeks of daily use.
Participants will take the Edge+Ease PM product (one serving of powder mixed in approximately 150-250 mL water) in the evening approximately 60-90 minutes before bedtime, and the Edge+Ease AM product (two capsules) in the morning with food. All study activities are conducted remotely via the Citruslabs platform. Participants will complete questionnaires at Baseline, Week 4, Week 8, and Week 12, and will wear a Fitbit continuously beginning 7 days before product use through the end of the 12-week intervention period to provide objective sleep data.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Patrick Renner
- Numero di telefono: 4242450284
- Email: hello@citruslabs.com
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Male and female adults aged 18 to 65 years.
- Self-reports difficulty falling asleep, staying asleep, or having poor sleep quality overall, in the last 4 weeks.
- Self-reports seeking support in at least one of the following domains: Difficulty switching off, perceived stress load, mental overload, next-day mental fatigue, reduced mental clarity or reduced cognitive readiness.
- Generally healthy.
- Willing and able to take the PM product (one serving mixed in water) in the evening and the AM product (two capsules with food) in the morning daily for 12 weeks.
- Willing to maintain current diet, exercise, caffeine, alcohol, and sleep routines for the duration of the study.
- Willing to wear a Fitbit continuously during the trial, and for 7 days prior to starting the test product.
- Resides in the United States.
Exclusion Criteria:
- Known allergy or hypersensitivity to any ingredient in the test product.
- Currently pregnant, breastfeeding, or trying to conceive, or will be during the study period.
- Currently undergoing treatment for cancer, or have had a serious illness requiring hospitalization in the last 3 months.
- Diagnosed severe psychiatric disorder (e.g., bipolar disorder, schizophrenia, major depressive disorder requiring active treatment adjustment) that, in the judgment of the Investigator, would compromise participation or interpretation of results.
- Diagnosed inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), celiac disease, or other significant gastrointestinal condition requiring active management.
- Current use of prescription antidepressants/anxiolytics, or other prescription neurologically-active medications that have been initiated or had a dose change within the past 90 days.
- Current use of prescription sleep medications.
- Regular use (i.e. more than once per week) of melatonin, sedating antihistamines, CBD/THC used for sleep, valerian, ashwagandha, or other sleep-targeted supplements.
- Initiation of a new dietary supplement targeted at sleep, mood, cognition, or digestion within the 30 days prior to enrollment, or planning to start such a supplement during the study.
- Heavy drinkers, defined as more than 8 alcoholic drinks per week for women and more than 15 alcoholic drinks per week for men.
- Currently taking thyroid medication.
- Currently testing, or plan to in the next 12 weeks, a product for another research study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Edge+ease PM Arm
|
All enrolled participants receive the Edge+Ease PM+AM system daily for 12 weeks.
The PM product (powder) is taken as one serving mixed in approximately 150-250 mL water, around 60-90 minutes before intended bedtime, ideally after dinner.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Fitbit-measured sleep quality score
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12
|
Mean change in Fitbit sleep quality score from baseline, based on the average of three days per time point
|
Baseline, Week 4, Week 8, and Week 12
|
|
Change in Fitbit-measured time asleep
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12
|
Mean change in total time asleep from baseline, measured via Fitbit, based on the average of three days per time point
|
Baseline, Week 4, Week 8, and Week 12
|
|
Change in Fitbit-measured time awake
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12
|
Mean change in time awake from baseline, measured via Fitbit, based on the average of three days per time point
|
Baseline, Week 4, Week 8, and Week 12
|
|
Change in Fitbit-measured deep sleep
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12
|
Mean change in deep sleep duration from baseline, measured via Fitbit, based on the average of three days per time point
|
Baseline, Week 4, Week 8, and Week 12
|
|
Change in Fitbit-measured REM sleep
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12
|
Mean change in REM sleep duration from baseline, measured via Fitbit, based on the average of three days per time point
|
Baseline, Week 4, Week 8, and Week 12
|
|
Change in Fitbit-measured light sleep
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12
|
Mean change in light sleep duration from baseline, measured via Fitbit, based on the average of three days per time point
|
Baseline, Week 4, Week 8, and Week 12
|
|
Change in self-reported perceived sleep quality
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12
|
Mean change in perceived sleep quality assessed via questionnaire including the validated Sleep Quality Scale
|
Baseline, Week 4, Week 8, and Week 12
|
|
Change in self-reported sleep satisfaction
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12
|
Mean change in sleep satisfaction assessed via questionnaire including the validated Sleep Quality Scale
|
Baseline, Week 4, Week 8, and Week 12
|
|
Change in self-reported waking refreshed
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12
|
Mean change in self-reported waking refreshed assessed via questionnaire including the validated Sleep Quality Scale
|
Baseline, Week 4, Week 8, and Week 12
|
|
Change in self-reported morning readiness
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12
|
Mean change in self-reported morning readiness assessed via questionnaire including the validated Sleep Quality Scale
|
Baseline, Week 4, Week 8, and Week 12
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in self-reported mood
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12
|
Mean change in self-reported mood assessed via questionnaire administered through the study platform
|
Baseline, Week 4, Week 8, and Week 12
|
|
Change in self-reported calm
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12
|
Mean change in self-reported calm assessed via questionnaire administered through the study platform
|
Baseline, Week 4, Week 8, and Week 12
|
|
Change in self-reported evening wind-down
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12
|
Mean change in self-reported evening wind-down assessed via questionnaire administered through the study platform
|
Baseline, Week 4, Week 8, and Week 12
|
|
Change in self-reported emotional steadiness
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12
|
Mean change in self-reported emotional steadiness assessed via questionnaire administered through the study platform
|
Baseline, Week 4, Week 8, and Week 12
|
|
Change in self-reported irritability
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12
|
Mean change in self-reported irritability assessed via questionnaire administered through the study platform
|
Baseline, Week 4, Week 8, and Week 12
|
|
Change in self-reported mental clarity
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12
|
Mean change in self-reported mental clarity assessed via questionnaire administered through the study platform
|
Baseline, Week 4, Week 8, and Week 12
|
|
Change in self-reported focus
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12
|
Mean change in self-reported focus assessed via questionnaire administered through the study platform
|
Baseline, Week 4, Week 8, and Week 12
|
|
Change in self-reported digestive comfort
Lasso di tempo: Baseline, Week 4, Week 8, and Week 12
|
Mean change in self-reported digestive comfort assessed via questionnaire administered through the study platform
|
Baseline, Week 4, Week 8, and Week 12
|
|
Participant perception of product effect on sleep quality
Lasso di tempo: Week 4, Week 8, and Week 12
|
Participant-reported perception of product effects on sleep quality assessed via questionnaire administered through the study platform
|
Week 4, Week 8, and Week 12
|
|
Participant perception of product effect on sleep satisfaction
Lasso di tempo: Week 4, Week 8, and Week 12
|
Participant-reported perception of product effects on sleep satisfaction assessed via questionnaire administered through the study platform
|
Week 4, Week 8, and Week 12
|
|
Participant perception of product effect on waking refreshed
Lasso di tempo: Week 4, Week 8, and Week 12
|
Participant-reported perception of product effects on waking refreshed assessed via questionnaire administered through the study platform
|
Week 4, Week 8, and Week 12
|
|
Participant perception of product effect on morning readiness
Lasso di tempo: Week 4, Week 8, and Week 12
|
Participant-reported perception of product effects on morning readiness assessed via questionnaire administered through the study platform
|
Week 4, Week 8, and Week 12
|
|
Participant perception of product effect on mood
Lasso di tempo: Week 4, Week 8, and Week 12
|
Participant-reported perception of product effects on mood assessed via questionnaire administered through the study platform
|
Week 4, Week 8, and Week 12
|
|
Participant perception of product effect on calmness
Lasso di tempo: Week 4, Week 8, and Week 12
|
Participant-reported perception of product effects on calmness assessed via questionnaire administered through the study platform
|
Week 4, Week 8, and Week 12
|
|
Participant perception of product effect on evening wind-down
Lasso di tempo: Week 4, Week 8, and Week 12
|
Participant-reported perception of product effects on evening wind-down assessed via questionnaire administered through the study platform
|
Week 4, Week 8, and Week 12
|
|
Participant perception of product effect on task initiation
Lasso di tempo: Week 4, Week 8, and Week 12
|
Participant-reported perception of product effects on task initiation assessed via questionnaire administered through the study platform
|
Week 4, Week 8, and Week 12
|
|
Participant perception of product effect on mental clarity
Lasso di tempo: Week 4, Week 8, and Week 12
|
Participant-reported perception of product effects on mental clarity assessed via questionnaire administered through the study platform
|
Week 4, Week 8, and Week 12
|
|
Participant perception of product effect on focus
Lasso di tempo: Week 4, Week 8, and Week 12
|
Participant-reported perception of product effects on focus assessed via questionnaire administered through the study platform
|
Week 4, Week 8, and Week 12
|
|
Participant perception of product effect on digestive comfort
Lasso di tempo: Week 4, Week 8, and Week 12
|
Participant-reported perception of product effects on digestive comfort assessed via questionnaire administered through the study platform
|
Week 4, Week 8, and Week 12
|
|
Participant perception of product effect on gut health
Lasso di tempo: Week 4, Week 8, and Week 12
|
Participant-reported perception of product effects on gut health assessed via questionnaire administered through the study platform
|
Week 4, Week 8, and Week 12
|
|
Participant perception of product effect on overall wellness
Lasso di tempo: Week 4, Week 8, and Week 12
|
Participant-reported perception of product effects on overall wellness assessed via questionnaire administered through the study platform
|
Week 4, Week 8, and Week 12
|
|
Incidence of adverse events
Lasso di tempo: Throughout study (up to 12 weeks)
|
Number and percentage of participants experiencing adverse events, characterized by severity and relationship to study product, assessed via self-report questionnaire and investigator review
|
Throughout study (up to 12 weeks)
|
|
Severity of adverse events
Lasso di tempo: Throughout study (up to 12 weeks)
|
Severity rating (mild, moderate, severe) of adverse events assessed via self-report questionnaire and investigator review
|
Throughout study (up to 12 weeks)
|
|
Participant discontinuations due to adverse events
Lasso di tempo: Throughout study (up to 12 weeks)
|
Number of participants who discontinue the study intervention due to adverse events
|
Throughout study (up to 12 weeks)
|
Collaboratori e investigatori
Sponsor
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- EDGEE-27795
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .